Document is current
Any future updates will be listed below
-
Authors
Alshawa, Anas
Cadena, Alexandra Perez
Stephen, Bettzy
Reddy, Akhila
Mendoza, Tito R.
McQuinn, Lacey
Lawhorn, Kristie
Zarifa, Abdulrazzak
Bernhardt, Alexander Maximilian
Fessaheye, Senait
Warneke, Carla L.
Chang, Joe Y. https://orcid.org/0000-0002-8435-2083
Naing, Aung
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (P30CA016672)
- License Information
-
More Information
Article History
Received: 20 November 2020
Accepted: 25 January 2021
First Online: 13 February 2021
Declarations
:
: The protocol was approved by the Institutional Review Board at MD Anderson and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. All study participants provided written informed consent before enrollment.
: All study participants provided written informed consent before enrollment which include consent for publication.
: Dr. Aung Naing: research funding from NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor/Millendo; Amplimmune; ARMO BioSciences; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; BMS; Pfizer, CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Eli Lilly; Kymab; PsiOxus; Arcus Biosciences; NeoImmuneTech; ImmuneOncia; Surface Oncology. On advisory board of CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695 and Kymab. Travel and accommodation expense from ARMO BioSciences.Dr. Aung Naing’s Spouse: Dr. Joud Hajjar: research funding: Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. Advisory board: Takeda, CSL, Behring, Horizon, and Pharming.No other conflict of interest or competing interests to disclose for all other authors and statements has been provided.
